biliary tract cancer

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

News

Redx slumps after it abandons trial of lead cancer drug

Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.

News

Merck's Keytruda flunks another prostate cancer test

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.

News

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Jazz and Zymeworks enter exclusive zanidatamab agreement

Jazz Pharmaceuticals and Zymeworks, Inc. have announced that Jazz and Zymeworks BC, Inc.

News

FDA gives AZ the nod for Imfinzi in biliary tract cancer

AstraZeneca's checkpoint inhibitor Imfinzi has become the first immunotherapy to be approved by the FDA for biliary tract cancer (BTC), a rare and aggressive form of cancer with limited tre

Imfinzi faces Keytruda competition in biliary tract cancer

Redx slumps after it abandons trial of lead cancer drug

Merck's Keytruda flunks another prostate cancer test

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Jazz and Zymeworks enter exclusive zanidatamab agreement

FDA gives AZ the nod for Imfinzi in biliary tract cancer

Ex-BioNTech execs launch 'AI-native' cancer company

Discover a new era of healthcare panel engagement: Grounded ...

biliary tract cancer

Editor's Picks